Search
Vespula vulgaris venom protein
go.drugbank.com/drugs/DB11033ApprovedVespula vulgaris venom protein is an extract of Vespula vulgaris venom. Vespula vulgaris venom protein is used in allergenic testing.
Mixtures: Venomil Inj Mixed 300mcg/dose, Mixed Vespid Venom Protein InjProducts: ALUTARD SQ Wespengift Injektionssuspension (Anfangsbehandlung) (100 SQ E/ml, 1.000 SQ E/ml, 10.000 SQ E/ml und 100.000 SQ E/ml), Wasp Venom Protein InjAluminum acetate
go.drugbank.com/drugs/DB14518ApprovedInvestigationalMixtures: Zo Medical Zo Post Procedure Recovery System, ZISUAL-CProducts: ACID MANTLE® N LOCION., ACID MANTLE N LOCIONTuroctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalTuroctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human or animal-derived materials [F3685]. … The essential difference between turoctocog alfa and N8-GP, however, is the specific attachment of a 40-kDa polyethylene glycol (PEG) group to a specific _O_-glycan in the truncated B-domain of the general
Products: ESPEROCT® 1500 UI, ESPEROCT® 2000 UIBisacodyl
go.drugbank.com/drugs/DB09020ApprovedInvestigationalBisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation. … [A233290,A233300,A207700] Bisacodyl was patented on 25 September 1956[L33045] but has been used as a laxative since 1952.[A233300]
Mixtures: Bi-peglyte, BEKUNIS 3 MG/5 MG KAPLI TABLET, 30 ADETSynonyms: Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester)Silver sulfadiazine
go.drugbank.com/drugs/DB05245ApprovedInvestigationalVet approvedSilver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.
Mixtures: SİLVERDİN PLUS %1 + %5 KREM, 50 G, Flamazine CCategories: combinations of sulfonamidesZonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigationalZonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures. … [L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan.
Categories: Compounds used in a research, industrial, or household setting, combinations of sulfonamidesSynonyms: Benzo[d]isoxazol-3-yl-methanesulfonamide, 1,2-Benzisoxazole-3-methanesulfonamideTolcapone
go.drugbank.com/drugs/DB00323ApprovedInvestigationalWithdrawnTolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. … It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsSynonyms: 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone, 3,4-dihydroxy-5-nitro-4'-methylbenzophenoneIobenguane
go.drugbank.com/drugs/DB06704ApprovedInvestigationalIodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008. … The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline.
Salts: Iobenguane I 123, Iobenguane I 131Categories: Compounds used in a research, industrial, or household setting, Diagnostic Uses of ChemicalsOlopatadine
go.drugbank.com/drugs/DB00768Approved[A179809] Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations … [A1172] In comparison to other anti-allergenic ophthalmic medications, olopatadine displays a good comfort and tolerability profile since it does not cause perturbation of cell membranes.
Mixtures: OFNOL FRESH % 0.1 + %0.15 STERİL OFTALMİK ÇÖZELTİ, 1 ADETCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesBortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigational[A204146] Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis … [L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083] Bortezomib was first synthesized in 1995.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide, [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid